Comparing physician-reported cancer management plans with medicare services received

Archives of Internal Medicine

Volumn 172, Issue 8, 2012, Pages 664-666

  Henderson, Louise M ^a   Reeder Hayes, Katherine ^a,c   Hinton, Sharon Peacock ^d   Carpenter, William R ^b,c   Chen, Ronald C ^a,c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d Carolinas Center for Medical Excellence   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURGERY; CANCER THERAPY; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; HEALTH CARE COST; HEALTH CARE PLANNING; HUMAN; KIDNEY BIOPSY; KIDNEY CARCINOMA; LETTER; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MEDICARE; PANCREAS ADENOCARCINOMA; PANCREAS BIOPSY; PHYSICIAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BIOPSY; CARCINOMA, RENAL CELL; COHORT STUDIES; DIAGNOSTIC IMAGING; DISEASE MANAGEMENT; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MEDICAL RECORD LINKAGE; MEDICARE; NEOPLASMS; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; REGISTRIES; RETROSPECTIVE STUDIES; UNITED STATES; WATCHFUL WAITING;

EID: 84860378467     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2012.271     Document Type: Letter

References (8)

1. Lindsay MJ, Siegel BA, Tunis SR, et al. The National Oncologic PET Registry: expanded Medicare coverage for PET under coverage with evidence development. AJR Am J Roentgenol. 2007;188(4):1109-1113. (Pubitemid 46496951)
2. Centers for Medicare and Medicaid Services. National coverage determination (NCD) for FDG PET for brain, cervical, ovarian, pancreatic, small cell lung, and testicular cancers (220.6.14). https://www.cms.gov /medicare-coverage-database/details/ncd-details.aspx?NCDId =295&ncdver= 2&NCAId=92&ver=19&NcaName=Positron+Emission +Tomography+&bc= BEAAAAAAIAAA&. Accessed February 10, 2012.
3. Tunis SR, Pearson SD. Coverage options for promising technologies: Medicare's 'coverage with evidence development'. Health Aff (Millwood). 2006; 25(5):1218-1230. (Pubitemid 44497620)
4. Hillner BE, Liu D, Coleman RE, et al. The National Oncologic PET Registry (NOPR): design and analysis plan. J Nucl Med. 2007;48(11):1901-1908. (Pubitemid 350099337)
5. Hillner BE, Siegel BA, Liu D, et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol. 2008;26(13):2155-2161.
6. Hillner BE, Siegel BA, Shields AF, et al. The impact of positron emission tomography (PET) on expected management during cancer treatment: findings of the National Oncologic PET Registry. Cancer. 2009;115(2):410-418.
7. Hillner BE, Siegel BA, Shields AF, et al. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry. J Nucl Med. 2008;49(12):1928-1935.
8. Tunis S, Whicher D. The National Oncologic PET Registry: lessons learned for coverage with evidence development. J Am Coll Radiol. 2009;6(5):360-365.